
|Articles|March 22, 2004
New biologic offers hope as first-line colorectal cancer agent
The FDA recently approved bevacizumab (Avastin, Genentech) for use in combination with intravenous 5-fluorouracil-based chemotherapy for the first-line treatment of metastatic CRC. Bevacizumab is the first angiogenesis inhibitor to be approved for use in the U.S. Genentech began to ship bevacizumab to wholesalers within 3 days of its approval.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
4
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
5




























